Lipoproteins: From A to B and maybe C-III

International Journal of Clinical Practice

Volumn 62, Issue 5, 2008, Pages 674-676

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN F; APOLIPOPROTEIN G; APOLIPOPROTEIN N; ARYLDIALKYLPHOSPHATASE; BETA 2 MICROGLOBULIN; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CHOLESTEROL; CLUSTERIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SIALOGLYCOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOCYTE; CHOLESTEROL TRANSPORT; EDITORIAL; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; SATIETY;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; APOLIPOPROTEINS B; HUMANS;

EID: 42149091749     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01718.x     Document Type: Editorial

References (27)

1. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 : 937 52.
2. Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001 358 : 2026 33.
3. Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986 256 : 2835 8.
4. Barter PJ, Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 2006 259 : 447 54.
5. Tailleux A, Duriez P, Fruchart JC et al. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002 164 : 1 13.
6. Stan S, Delvin E, Lambert M et al. Apo A-IV: an update on regulation and physiologic functions. Biochim Biophys Acta 2003 1631 : 177 87.
7. Calandra S, Priore OC, Tarugi P et al. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol 2006 17 : 122 7.
8. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001 12 : 297 304.
9. Fojo SS, Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 1992 231 : 669 77.
10. Chan DC, Chen MM, Ooi EMM, Watts GF. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008 62 : 799 809.
11. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999 19 : 472 84.
12. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000 1 : 507 37.
13. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999 10 : 207 17.
14. Campos H, Perlov D, Khoo C et al. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001 42 : 1239 49.
15. Davidsson P, Hulthe J, Fagerberg B et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005 46 : 1999 2006.
16. Auwerx J, Schoonjans K, Fruchart JC et al. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 1996 3 : 81 9.
17. Rassart E, Bedirian A, Do CS et al. Apolipoprotein D. Biochim Biophys Acta 2000 1482 : 185 98.
18. Morton RE, Gnizak HM, Greene DJ et al. Lipid transfer inhibitor protein (apolipoprotein F) concentration in normolipidemic and hyperlipidemic subjects. J Lipid Res 2008 49 : 127 35.
19. Okamoto Y. Other apolipoproteins (apolipoprotein F, G, H, L, M and so on). Nippon Rinsho 2004 62 (Suppl. 12 123 6.
20. McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog Lipid Res 2003 42 : 176 237.
21. Calero M, Rostagno A, Matsubara E et al. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 2000 50 : 305 15.
22. Vanhollebeke B, Pays E. The function of apolipoproteins L. Cell Mol Life Sci 2006 63 : 1937 44.
23. Dahlback B, Nielsen LB. Apolipoprotein M - a novel player in high-density lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 2006 17 : 291 5.
24. O'Bryan MK, Foulds LM, Cannon JF et al. Identification of a novel apolipoprotein, ApoN, in ovarian follicular fluid. Endocrinology 2004 145 : 5231 42.
25. Karlsson H, Leanderson P, Tagesson C et al. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005 5 : 551 65.
26. Rezaee F, Casetta B, Levels JH et al. Proteomic analysis of high-density lipoprotein. Proteomics 2006 6 : 721 30.
27. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007 117 : 746 56.